A trial fibrillation (AF) is an independent, modifiable risk factor for ischemic stroke 1 and independently associated with increased mortality.
Methods. Using the Medicare 5% database, we identified patients with prevalent AF among general Medicare enrollees (aged Ն65 years, excluding end-stage renal disease) for each cohort year, 1992 through 2007. We subsequently calculated ischemic and hemorrhagic stroke rates and warfarin use in each cohort year among patients with prevalent AF. The Medicare 5% database is a rolling replacement cohort provided annually by the Centers for Medicare & Medicaid Services, composed of a random sample of 5% of all Medicare beneficiaries. Patients with at least 1 were excluded. For prevalent and incident AF, an AF date was established as the date of the first AF claim during the year. Stroke rates and warfarin use were identified during the year after the AF date. Strokes were identified from inpatient Medicare claims, with stroke as the principal diagnosis (ICD-9-CM codes 434.x and 436.x for ischemic stroke; and codes 430.x and 431.x for hemorrhagic stroke). A previously described surrogate method was used to identify warfarin-treated patients with AF using at least 3 prothrombin time claims during the year after the AF date. 6 The institutional review board at Hennepin County Medical Center approved the study. with 1992, this represented a 65% decrease in ischemic stroke in the Medicare population. In contrast, the hemorrhagic stroke rate remained constant at nearly 2 per 1000 patient-years throughout the study period. This study is limited owing to the observational design; the declining rates of ischemic stroke with increasing warfarin use reflect temporal associations and not necessarily the effect of anticoagulation. We used a surrogate method to ascertain warfarin use, which could result in underestimating numbers of individuals undergoing testing in alternative settings.
In conclusion, ischemic stroke rates continue to decrease in the Medicare population, parallel to increases in warfarin use, although these rates appear to have leveled off. On the basis of these data, the 37% of Medicare beneficiaries not currently receiving warfarin for anticoagulation may offer a window of opportunity for further reduction in ischemic stroke rates and should be targeted in future studies. 
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Author Contributions: Dr Herzog had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The analysis, interpretation, and reporting of these data are the responsibility of the authors. 1 A health care provider's EHR progress notes are essential for effective communication. However, these notes may increase errors when they are difficult to read.
2 Billing requirements, regulatory statements, and extensive inclusion of test results detract from progress note brevity and clarity. 3 In our experience, EHR progress notes that include such elements can span 17 electronic pages, rendering actual clinical reasoning extraordinarily difficult to locate. Missing data can lead to lost productivity and increased cost. 4 Health care providers' frustration with EHR progress notes may interfere with EHR adoption 5, 6 and deployment. 7 Although the traditional SOAP (Subjective, Objective, As- 
